Online inquiry

IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10022MR)

This product GTTS-WQ10022MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FN gene. The antibody can be applied in Lymphoproliferative disease research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10022MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8090MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ11737MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ7293MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ15998MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ6567MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ1488MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ15776MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ12357MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA N63Ab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW